Refine by
697 results found
-
Early Qualitative Research Of AI-Driven Mental Health Therapy
In a recent qualitative study, researchers explored the feasibility of artificial intelligence (AI) as a source of mental health support. Fourteen participants with mild-to-moderate anxiety or depression engaged in one immersive virtual reality therapy session with an AI therapy avatar. Participants overall considered the digital avatar empathetic, understanding, and supportive of a therapeutic relationship, but some indicated a preference for the deeper engagement possible with a human therapist. Personal comfort with AI varies and more research is needed to determine clinical effectiveness, but AI-driven therapy may one day represent another tool to support mental health. To learn more, see the study in npj Digital Medicine. -
Letter to Congressional Committee Leadership on Health Coverage and Telehealth
Letter to House and Senate appropriations subcommittee leadership opposing the Telehealth Benefit Expansion for Workers Act of 2023 (H.R. 824), which would allow employers to offer workers stand-alone telehealth benefits. -
Ethnoracial Representation In Psychosis Research
Inclusion of BIPOC individuals (Black, Indigenous, and people of color) in clinical research is critical for understanding how conditions develop in different populations. In a systematic review, researchers explored participant data from 12 North American multisite research studies of clinical high risk for psychosis and first episode psychosis (FEP). Most ethnoracial groups were appropriately represented in high risk studies based on their share of the U.S. population; Black participants were overrepresented in FEP studies. Inclusion of BIPOC individuals in both types of studies is encouraging, but opportunities exist to most effectively incorporate diverse backgrounds into psychosis research. To learn more, see the study in Psychiatric Services. -
Regulatory Comment on Health Coverage and Crisis Services
Regulatory comment to Treasury Secretary Yellen, Secretary Becerra, and CMS Administrator Brooks-LaSure on the Notice of Benefit and Payment Parameters for 2025 Proposed Rule, focusing on the need to encourage state coverage of crisis response services as an Essential Health Benefit. -
Regulatory Comment on Health Coverage
Regulatory comment to Treasury Secretary Yellen, HHS Secretary Becerra, and CMS Administrator Brooks-LaSure on the Notice of Benefit and Payment Parameters for 2025 Proposed Rule, offering recommendations to address specific provisions of the proposed rule. -
Large Study Finds Semaglutide Medications Associated With Lower Risk For Suicidal Ideation Than Other Obesity And Diabetes Drugs
Amidst increasing popularity of semaglutide medications such as Wegovy and Ozempic, concerns have been raised that the glucagon-like peptide 1 receptor (GLP1R) agonist medications may increase suicidal thoughts. In a recent study, researchers analyzed electronic health records for 240,000 people being treated for excess weight or obesity with either semaglutide or a non-GLP1R medication. Treatment with semaglutide was associated with lower risk for suicidal ideation compared to non-GLP1R medications across demographic groups. Findings were replicated in 1.5 million people with type 2 diabetes being treated to lower blood pressure. To learn more, see the study in Nature. -
Statement on Health Coverage
Statement applauding the Department of Labor’s newly proposed rule strengthening consumer protections in association health plans (AHPs). -
Regulatory Comment To CMCS And HHS On Parity And Medicaid
Regulatory comment to the Center for Medicaid and CHIP Services (CMCS) on Processes for Assessing Compliance with Mental Health Parity and Addiction Equity in Medicaid and the Children’s Health Insurance Program (CHIP). -
Regulatory Comment To CMCS On Parity
Regulatory comment to the Center for Medicaid and CHIP Services (CMCS) on Processes for Assessing Compliance with Mental Health Parity and Addiction Equity in Medicaid and the Children’s Health Insurance Program (CHIP). -
Regulatory Comment To CMCS On Parity And Medicaid
Regulatory comment to the Center for Medicaid and CHIP Services (CMCS) on Processes for Assessing Compliance with Mental Health Parity and Addiction Equity in Medicaid and the Children’s Health Insurance Program (CHIP).